Recombinant anti-osteopontin antibody and use thereof
CA 2461529 A1 · Owner: Maeda, Hiroaki · Inventors: Torikai, Masaharu; Uede, Toshimitsu; Yamamoto, Nobuchika
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus a method of treating autoimmune diseases rheumatism or rheumatoid arthritis , is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 25, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 25, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 25, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.